NIH Highlighted Topic: Advancing the Use of Genomic Information Into Clinical Care
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is seeking innovative research proposals through the SBIR Program focused on advancing the use of genomic information in clinical care. NIH is particularly interested in technologies, platforms, and implementation strategies that improve patient outcomes by integrating genomic evidence into routine healthcare delivery, precision medicine, disease prevention, diagnostics, and treatment decision-making.
Although genomic variants are known to influence risk for numerous diseases, significant gaps remain in demonstrating how genomic information improves clinical outcomes, cost-effectiveness, care delivery, and long-term health management. NIH is encouraging projects that generate genomic medicine evidence, develop scalable implementation frameworks, and create clinical tools and data resources that enable broader adoption of evidence-based genomic medicine. Companies developing genomics platforms, AI-enabled clinical decision support tools, multi-omic data systems, precision medicine technologies, predictive analytics solutions, diagnostics, digital health platforms, or genomic workflow integration technologies may be strong candidates for funding.
NIH is especially interested in projects focused on implementation science, genomic clinical utility, healthcare workflow integration, patient-centered genomic care, infectious disease genomics, addiction genomics, neurological applications, women’s health genomics, cancer genomics, and translational genomic data infrastructure. Research that improves accessibility, scalability, and real-world implementation of genomic medicine across diverse patient populations and healthcare environments is also encouraged.
Through the NIH SBIR Program, U.S. small businesses may apply for up to $323,090 in Phase I funding and up to $2,153,927 in Phase II funding to support research, development, validation, and commercialization activities. Applications are accepted on January 5th, April 5th, and September 5th annually, with funding typically beginning approximately 9 months after submission.
This highlighted topic is supported primarily by the National Human Genome Research Institute (NHGRI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Nursing Research (NINR), the National Cancer Institute (NCI), the National Institute of Dental and Craniofacial Research (NIDCR), and the Office of Research on Women’s Health (ORWH), all of which may give special consideration to high-impact applications advancing precision medicine, genomic healthcare integration, and translational clinical genomics.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of technologies and clinical solutions that advance the integration of genomic information into healthcare delivery and precision medicine.
Eligible activities may include:
Development of genomic diagnostics, predictive analytics tools, or precision medicine platforms
AI and machine learning systems for genomic interpretation, risk prediction, and clinical decision support
Multi-omic data repositories and translational genomic research infrastructure
Clinical workflow integration tools for genomic medicine implementation
Research evaluating clinical utility, patient outcomes, and cost-effectiveness of genomic interventions
Technologies supporting personalized prevention, diagnosis, and treatment strategies
Genomic medicine implementation science and healthcare adoption research
Pathogen, microbiome, infectious disease, or HIV-related genomic applications
Addiction and substance use genomics platforms and predictive models
Neurological, oncology, autoimmune, and women’s health genomic research technologies
Population health and community-based genomic medicine approaches
Genomic data visualization, interoperability, and healthcare integration systems
Biomarker discovery and genomic variant interpretation platforms
Digital health tools supporting genomic-guided patient engagement and care management
Validation studies, translational research, prototype development, and regulatory preparation activities
Commercialization planning and scale-up activities for genomics and precision medicine technologies
Funding may also support personnel, software development, laboratory testing, cloud or computational infrastructure, clinical data analysis, prototype fabrication, intellectual property protection, commercialization strategy development, and other research and development activities necessary to advance a commercially viable solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
